{"id":"NCT00801242","sponsor":"Ferring Pharmaceuticals","briefTitle":"Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer","officialTitle":"An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One or More Cycles in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2012-06","completion":"2013-07","firstPosted":"2008-12-03","resultsPosted":"2014-09-03","lastUpdate":"2014-09-03"},"enrollment":220,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Degarelix 240 mg / 80 mg","otherNames":["FE200486","Firmagon"]}],"arms":[{"label":"Degarelix 240 mg / 80 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this uncontrolled, multi-center, open-label trial was to investigate the feasibility of using degarelix as intermittent androgen deprivation (IAD) therapy in the treatment of prostate cancer.","primaryOutcome":{"measure":"Median and Between Participant Variability of Time to Prostate-specific Antigen (PSA) >4 ng/mL During the First Cycle of Intermittent Androgen Deprivation (IAD) After 7 Monthly Injections of Degarelix Induction Treatment","timeFrame":"Up to 24 months after end of induction period","effectByArm":[{"arm":"Degarelix 240 mg / 80 mg","deltaMin":392,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":52,"countries":["Belgium","France","Germany","Italy","Netherlands","Spain"]},"refs":{"pmids":["28753747","24954791"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":51,"n":216},"commonTop":["Hot Flush","Injection Site Pain","Injection Site Erythema","Injection Site Swelling","Injection Site Induration"]}}